Cardiff Oncology (NASDAQ:CRDF) Announces Earnings Results

Cardiff Oncology (NASDAQ:CRDF) posted its quarterly earnings results on Thursday. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02, Zacks reports. Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%.

Cardiff Oncology Trading Down 2.7%

NASDAQ:CRDF traded down $0.02 during midday trading on Thursday, reaching $0.74. The company had a trading volume of 140,076 shares, compared to its average volume of 1,026,652. Cardiff Oncology has a 12-month low of $0.72 and a 12-month high of $3.31. The firm has a market capitalization of $57.96 million, a price-to-earnings ratio of -1.24 and a beta of 1.57. The stock’s fifty day simple moving average is $1.05 and its 200-day simple moving average is $1.37.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CRDF. William Blair lowered Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 11th. Weiss Ratings raised Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. HC Wainwright upgraded shares of Cardiff Oncology from a “neutral” rating to a “buy” rating in a report on Tuesday, September 15th. Finally, Wall Street Zen upgraded shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $7.50.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division. Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer.